Oncolytic viruses and cytokine-based gene therapies reprogram the tumor microenvironment
Combining oncolytic viruses with immune therapies shows promise for reawakening suppressed anti-tumor immunity in difficult-to-treat cancers.
This review in Nature Cancer synthesizes translational insights from recent clinical trials of oncolytic viruses and cytokine-based gene therapies, which can convert 'cold' immunosuppressive tumors into immune-responsive states. It identifies key barriers to durable responses and highlights emerging combinatorial strategies aimed at amplifying antitumor immunity.
What the study was
- Study design
- Review
- Population
- Solid tumor patients receiving oncolytic virus or cytokine gene therapy
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Nature Cancer
Why it surfaced
Nature Cancer review synthesizing TME reprogramming landscape with clinical data; high relevance for immunotherapy pipeline understanding despite being a review.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.